

Haematologica  
HAEMATOL/2019/226795  
Version 3

The novel L-nucleoside analogue, 5-Fluorotroxacitabine, displays  
potent efficacy against acute myeloid leukemia

Aniket Bankar, Thirushi Piyumika Siriwardena, Biljana Rzoska,  
Christina Rydergård, Helen Kylefjord, Vilma Rraklli, Anders Eneroth,  
Pedro Pinho, Stefan Norin, Johan Bylund, Sara Moses, Richard  
Bethell, Simon Kavanagh, Neil Maclean, Marcela Gronda, Xiaoming  
Wang, Rose Hurren, Mark D. Minden, Paul Targett-Adams, Aaron D.  
Schimmer, and Mark Albertella

Disclosures: This work was supported by Medivir AB, the Canadian Institutes of Health Research, the Princess Margaret Cancer Centre Foundation, and the Ministry of Long Term Health and Planning in the Province of Ontario. ADS holds the Barbara Baker Chair in Leukemia and Related Diseases. BR was an employee of Medivir when the work was performed. MA and PTA were employees of Medivir at the time the research was performed, and have an equity share in the company. ADS received research funding from Medivir and has received consulting fees from Novartis, Jazz, and Otsuka Pharmaceuticals. ADS holds shares in Abbvie.

Contributions: AB, TPS, NM, MG, RH, XW, BR, SR, PTA, MA, performed research and analyzed data. BR, MA, PTA analyzed data, supervised research, provided critical reagents. ADS analyzed data and supervised research. AB, ADS, PTA and MA wrote the paper. All authors reviewed and edited the paper.